Primary care diabetes · 2014
Metabolic control and therapeutic profile of patients with diabetes in Portuguese primary care (TEDDI CP).
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cardoso Salvador Massano, Rodrigues Elisabete, Valadas Cristina, Fonseca Clara, TEDDI CP investigators
Аннотация
AIM: To evaluate the metabolic control rate and to characterize the therapeutic profile of patients with Type 2 diabetes mellitus (DM2) from Portuguese primary care of National Health Service.
METHODS: Cross-sectional multicentre study conducted in Portuguese primary health care units between July 2011 and May 2012. A national representative sample of 1528 DM2 patients was selected from 51 units, stratified by region. Socio-demographic, anthropometric, lifestyle, cardiometabolic risk factors, disease status, HbA1c levels and therapeutic information were collected.
RESULTS: Patients' mean age was 65±10.7 years (50.4% males) and median duration of disease was 7 years: range (0-45 years). Almost 8% were smokers, 80.3% had hypertension, 61.6% hypercholesterolemia and almost 15% cardiovascular disease. Patients' health condition was classified with a score of 4 or 5 (excellent) for 60.6%. Median HbA1c was 6.6% (min-max: 4.2%-13.4%), 64.8% of the patients had HbA1c<7.0% and 49.2% HbA1c≤6.5%. Oral antidiabetics were used in 94.4% of the patients, antihypertensives in 80.6%, antidyslipidemics in 72.0%, antiplatelet agents in 50.6% and insulin in 8.3%.
CONCLUSIONS: Metabolic control rate was good according to current guidelines. However, patients with higher HbA1c levels had longer time since diagnosis, worse current health condition, hypertriglyceridemia and were insulin-treated.
METHODS: Cross-sectional multicentre study conducted in Portuguese primary health care units between July 2011 and May 2012. A national representative sample of 1528 DM2 patients was selected from 51 units, stratified by region. Socio-demographic, anthropometric, lifestyle, cardiometabolic risk factors, disease status, HbA1c levels and therapeutic information were collected.
RESULTS: Patients' mean age was 65±10.7 years (50.4% males) and median duration of disease was 7 years: range (0-45 years). Almost 8% were smokers, 80.3% had hypertension, 61.6% hypercholesterolemia and almost 15% cardiovascular disease. Patients' health condition was classified with a score of 4 or 5 (excellent) for 60.6%. Median HbA1c was 6.6% (min-max: 4.2%-13.4%), 64.8% of the patients had HbA1c<7.0% and 49.2% HbA1c≤6.5%. Oral antidiabetics were used in 94.4% of the patients, antihypertensives in 80.6%, antidyslipidemics in 72.0%, antiplatelet agents in 50.6% and insulin in 8.3%.
CONCLUSIONS: Metabolic control rate was good according to current guidelines. However, patients with higher HbA1c levels had longer time since diagnosis, worse current health condition, hypertriglyceridemia and were insulin-treated.
Предметные рубрики MeSH
Administration, OralAdultAgedAged, 80 and overAntihypertensive AgentsBiomarkersComorbidityCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHealth StatusHumansHypercholesterolemiaHypertensionHypoglycemic AgentsHypolipidemic AgentsInjectionsInsulinLinear ModelsLogistic ModelsMaleMiddle AgedMultivariate AnalysisNational Health ProgramsPlatelet Aggregation InhibitorsPortugalPrevalencePrimary Health CareRisk FactorsSmokingTime FactorsTreatment Outcome